Rhumbline Advisers Has $233,000 Position in Sutro Biopharma, Inc. (NASDAQ:STRO)

Rhumbline Advisers boosted its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 6.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 126,698 shares of the company’s stock after buying an additional 7,320 shares during the quarter. Rhumbline Advisers owned approximately 0.15% of Sutro Biopharma worth $233,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Gladius Capital Management LP acquired a new position in shares of Sutro Biopharma during the third quarter valued at $28,000. China Universal Asset Management Co. Ltd. bought a new stake in Sutro Biopharma during the 4th quarter worth about $32,000. Vontobel Holding Ltd. raised its holdings in Sutro Biopharma by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $46,000 after purchasing an additional 10,000 shares during the last quarter. SG Americas Securities LLC lifted its position in Sutro Biopharma by 16.6% during the 4th quarter. SG Americas Securities LLC now owns 40,432 shares of the company’s stock valued at $74,000 after purchasing an additional 5,770 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Sutro Biopharma in the 3rd quarter valued at about $77,000. 96.99% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on STRO. JMP Securities reissued a “market outperform” rating and set a $17.00 price target on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Wells Fargo & Company dropped their target price on shares of Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Wedbush restated an “outperform” rating and issued a $8.00 price target on shares of Sutro Biopharma in a research report on Tuesday, December 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Sutro Biopharma in a report on Monday, November 18th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.13.

Sutro Biopharma Stock Up 2.0 %

STRO opened at $1.50 on Monday. The stock has a market cap of $123.69 million, a P/E ratio of -0.93 and a beta of 1.22. Sutro Biopharma, Inc. has a 12 month low of $1.32 and a 12 month high of $6.13. The company has a fifty day simple moving average of $1.82 and a 200 day simple moving average of $2.85.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.